Dr. Noah M. Hahn
Associate Professor of Oncology and Urology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, Maryland
Noah M. Hahn, MD, is Associate Professor of Oncology and Urology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, MD. Before joining Johns Hopkins, Dr. Hahn was the Director of the Genitourinary Medical Oncology Program at Indiana University, the chief scientific and chief medical officer for the Hoosier Oncology Group (HOG), co-chair of the HOG genitourinary oncology clinical trials working group, and co-founder of the HOG Bladder Cancer Clinical Trials Consortium. He was an Associate Professor in the Department of Medicine with an appointment in the Division of Hematology and Oncology. He attended medical school at the Indiana University School of Medicine in Indianapolis, Indiana where he received his MD degree in 2000. He completed a transitional year internship at Emory University in Atlanta, Georgia in 2001. He served as an internal medicine resident at Duke University in Durham, North Carolina from 2001-2003. He returned to Indiana and received his fellowship training at the Indiana University Melvin and Bren Simon Cancer Center (IUSCC) from 2003 through 2006. He joined the IUSCC clinical research faculty in July 2006 and was promoted to associate professor with tenure in July 2012. He currently serves as the genitourinary medical oncology director for the IUSCC, In addition, Dr. Hahn serves on the genitourinary oncology trials steering committee of the Eastern Cooperative Oncology Group and is a member of the National Cancer Institute’s Bladder Cancer Task Force. Dr. Hahn’s clinical and translational research interests focus on the: 1) The identification and validation of predictive biomarkers relevant to GU cancers, and 2) The identification of novel therapeutic and preventative targets for GU cancer patients. Dr. Hahn currently serves as the IUSCC lead investigator on multiple clinical trials of emerging prostate and bladder cancer therapeutic agents as well as novel imaging techniques.